Eli Lilly and Company

University of East Anglia

Other

Nicholas J Bach

Edmund C Kornfeld

Robert D Dillard

Susan Elizabeth Draheim

Jason Scott Sawyer

Richard Walter Schevitz

Daniel Jon Sall

Ho-Shen Lin

Richard Waltz Harper

John Michael Morin, Jr

Michael Enrico Richett

Jolie Anne Bastian

Stephen Richard Baker

Michael Dean Kinnick

Tulio Suarez

Edward David Mihelich

Michael Lyle Denney

Jeremy Gilmore

Russell Andrew Lewthwaite

Alexander McKillop

George Richard Stephenson

Robert B Hermann

Douglas Wade Beight

Michael LeRoy Phillips

Robert D Titus

Benjamin Alan Anderson

David A Hall

Robert Theodore Vasileff

Bennett C Laguzza

Nancy Kay Harn

Gary A Hite

Cynthia L Nichols

John Mcneill McGill, Iii

Michael William Urquhart

Richard James Loncharich

Gerald Floyd Smith

Alan David Palkowitz

Minsheng Zhang

Kumiko Takeuchi

Jefferson Ray McCowan

Robert J Foglesong

Mary George Johnson

James A Clemens

Nickolay Y Chirgadze

Michael P Lynch

Edmumd C Kornfeld

Michael William John Urquhart

A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA mediated release of fatty acids for treatment of conditions such as septic shock.

Substituted tricyclics

This invention relates to a method of making N-benzyl indoles, and to intermediates for use in the method, and to certain substantially optically pure N-benzyl indoles obtained by the method.

Process for preparing N-benzyl indoles

A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA mediated release of fatty acids for treatment of inflammatory diseases such as septic shock.

Indole sPLA2 inhibitors

A class of tricycles is disclosed together with the use of such for inhibiting Spla mediated release of fatty acids for the treatment of conditions such as septic shock.

A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.

1H-indole-3-glyoxylamide sPLA2 inhibitors

A class of novel oxime indoles is disclosed together with the use of such compounds for inhibiting sPLA mediated release of fatty acids for treatment of inflammatory diseases such as septic shock.

Oxime amide indole type sPLA2 inhibitors

This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.

Antithrombotic agents

A class of novel 1H-indole-3-acetamides is disclosed together with the use of such indole compounds for inhibiting sPLA,mediated release of fatty acids for treatment of conditions such as septic shock.

1H-indole-3-acetamide sPLA2 inhibitors

A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA,mediated release of fatty acids for treatment of conditions such as septic shock.

A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA,mediated release of fatty acids for treatment of conditions such as septic shock.

Process for preparing n-benzyl indoles

A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.

1H-indole-3-glyoxylamide sPLA.sub.2 inhibitors

Process for preparing 1H-indole-3-glyoxylamides

A class of novel pyrroles is disclosed together with the use of such compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.

Pyrroles as sPLA.sub.2 inhibitors

A process for producing a compound of the formu5la ##STR1## comprising the step of reacting a compound of the formula ##STR2## with a compound of the formula ##STR3## to form a compound of the formula ##STR4## wherein R.sup.2a is selected from the groups recited above for R.sup.2, or R.sup.2a --X-- is a protected hydroxyl group, and Z is a group of formula --Y--R.sub.5 recited above, or a group that can be converted into a group of said formula --Y--R.sup.5. Intermediates of formula IV and composition containing substantially optically pure enantiomers of Formula (I) are included within the scope of the invention.

Growing community of inventors

Indianapolis, IN, United States of America

Nicholas J Bach